Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed announced the redemption of all $225 million in outstanding 1.75% Convertible Senior Notes due 2025. The redemption date is set for August 9, 2024, and the redemption price will be 100% of the principal amount plus accrued interest, totaling approximately $1,001.17 per $1,000 principal. Interest on the Notes will cease to accrue after this date. Holders may convert their Notes into shares of Insmed common stock at a rate of 25.5384 shares per $1,000 principal until August 8, 2024. This conversion could result in up to 5,746,140 shares being issued if all Notes are converted.
Insmed, a global biopharmaceutical company, announced the granting of inducement awards to 15 new employees under NASDAQ Listing Rule 5635(c)(4). Approved by Insmed's Compensation Committee, the awards serve as a material inducement for their employment. On June 3, 2024, the employees received options to purchase 49,340 shares of Insmed common stock at $55.94 per share, the closing price on the grant date. The options have a 10-year term and a four-year vesting schedule, with 25% vesting after one year and 12.5% every six months thereafter, contingent on continued employment.
Insmed, a global biopharmaceutical company, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami. Management will engage in a fireside chat at 10:00 a.m. ET, which will be webcast live. The webcast will be accessible via Insmed's investor relations website and will remain archived for 30 days post-event.
Insmed will host a commercial webinar on June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for its key programs: ARIKAYCE®, brensocatib, and TPIP. Shareholders and interested parties can join the conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with access code 7504027. The call will also be webcast on Insmed's website and a replay will be available until July 4, 2024. The archived webcast will be accessible for 90 days in the Investor Relations section on the company’s site.
Insmed announced the pricing of a public offering of 12,621,359 shares of common stock at $51.50 per share, targeting $650 million in gross proceeds. An additional 1,893,203 shares are available to underwriters within a 30-day option. The funds will support research and development, commercialization of brensocatib, and other corporate purposes. Closing is expected on May 31, 2024, subject to customary conditions. Goldman Sachs, Leerink Partners, and J.P. Morgan lead the offering.
Insmed (Nasdaq: INSM), a biopharmaceutical company, has announced a proposed public offering of $500 million worth of its common stock. The company intends to provide underwriters with a 30-day option to purchase up to an additional 15% of the shares. All shares will be sold by Insmed, with Goldman Sachs & Co. and Leerink Partners acting as joint book-running managers. The offering is dependent on market conditions and other factors, and there is no assurance of its completion or terms. The public offering will be made through Insmed's shelf registration statement filed with the SEC, which became effective on May 19, 2023. Preliminary prospectus supplements will be available on the SEC's website in due course.
Insmed announced positive topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint, showing statistically significant reductions in pulmonary exacerbations (PEs) for both dosage strengths versus placebo. Secondary endpoints also showed significant improvements. Brensocatib was well-tolerated, and Insmed plans to file a New Drug Application with the FDA in Q4 2024, aiming for a mid-2025 U.S. launch. If approved, brensocatib would be the first treatment for bronchiectasis and the first dipeptidyl peptidase 1 (DPP1) inhibitor. Detailed results will be presented at an upcoming medical meeting.
Study findings included a 21.1% reduction in annualized rate of PEs for the 10 mg dose and 19.4% for the 25 mg dose. Secondary outcomes included an 18.7% and 17.5% prolongation in time to first PE for the respective doses. Brensocatib also showed improvements in forced expiratory volume and quality of life scores. The study engaged over 460 sites globally. Insmed will host an investor call on May 28, 2024, to discuss the results.
Insmed will host an investor call on May 28, 2024, at 8:00 am ET to discuss the topline results from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The company will release the results at 6:30 am ET, prior to the call. The ASPEN study is a global, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of brensocatib. The conference call can be accessed via phone or webcast, with a replay available until June 27, 2024.
Insmed presented positive data from its Phase 3 ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society 2024 International Conference. The study evaluated patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). ARIKAYCE combined with a macrolide-based regimen showed significantly greater improvements in respiratory symptoms and higher rates of culture conversion compared to the macrolide regimen alone. Quality of Life-Bronchiectasis (QOL-B) scores improved through Month 7 for ARIKAYCE patients, whereas improvements plateaued or worsened for the comparator group after Month 3. No patients developed resistance to ARIKAYCE or macrolides. Adverse event rates were higher in the ARIKAYCE arm but were consistent with expected safety profiles.
Insmed Incorporated reported total revenue of $75.5 million for the first quarter of 2024, showing 16% growth over the same period in 2023. The company highlighted positive safety and tolerability data from TPIP studies and encouraging results from PAH trials. They reiterated their 2024 revenue guidance of $340-360 million for global ARIKAYCE. Insmed continues to focus on commercial expansion, R&D for brensocatib and TPIP, and early-stage research programs.